SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: muddphudd who wrote (229)5/20/1998 12:58:00 AM
From: Jay Lowe  Read Replies (3) | Respond to of 586
 
Repeat of msg 133 ... burnrate.

CYPB Highlights

- 1Q results (.05) ... Gruss Report expected (.08)
- company has $7.4M short term cash available
- current burn rate $2.5M
- Prosorba Column device now being used for ITP
- Phase III trial of Prosorba for RA ended early
- CYPB to file PMA for RA indication of Prosorba mid-98
- Cyplex(tm) infusible platelet alternative Phase II trial in process
- Gruss report sets 2 month price target @ $6.75

last quarterly report approx msg 133



To: muddphudd who wrote (229)5/27/1998 10:03:00 AM
From: Meridian  Respond to of 586
 
<<Do we know what their burn-rate is right now?

Muddphudd,

Allen & Co is primarily an investment banker and has provided financing to CYPB over the last 5 or so years ... albeit at a steep price, because they were the only game in town. Now we've got a few more institutions/bankers following our stock and hopefully when CYPB needs a bridge loan with an equity kicker (most likely $5-$10 million) they can shop it around and get the best price.

Brian


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News